Transarterial Radioembolization (TARE)

What is transarterial radioembolization (TARE)?

Transarterial radioembolization (TARE) is a minimally invasive treatment that delivers radiation directly to tumors in the liver from the inside. It is also called selective internal radiation therapy (SIRT) or Y-90 radioembolization. During the treatment, an interventional radiologist (a doctor who performs image-guided procedures through small openings in the skin) threads a thin tube called a catheter into the arteries that feed the liver tumor. Millions of tiny beads, known as microspheres, are then released through the catheter. Each bead carries a radioactive isotope, most commonly yttrium-90 (Y-90). The beads lodge in the small blood vessels of the tumor and release radiation over a short distance for a period of days to weeks.

The word “transarterial” means the treatment travels through the arteries. “Radioembolization” combines two ideas: “radio” for radiation and “embolization” for partially blocking blood vessels. TARE works mainly through the radiation rather than through blocking blood flow, which distinguishes it from a related procedure called chemoembolization (TACE), where chemotherapy drugs and blocking particles are delivered through the same route.

Transarterial radioembolization is used for cancers that either start in the liver or have spread to it, including:

• Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, which often arises in a liver already damaged by cirrhosis (scarring) or chronic hepatitis.
• Intrahepatic cholangiocarcinoma, a cancer of the bile ducts inside the liver.
• Liver metastases, which are tumors that have spread to the liver from another site, most often colorectal cancer and sometimes neuroendocrine tumors, breast cancer, or melanoma.

TARE is usually considered a locoregional treatment, meaning it targets disease within the liver rather than treating cancer throughout the body. In many hospital systems, including Acibadem, it is delivered by the radiology department in cooperation with oncology, hepatology, nuclear medicine, and surgical teams.

Who needs transarterial radioembolization: candidates and exclusions

Deciding who needs transarterial radioembolization is a team decision, usually made at a multidisciplinary tumor board where specialists review the scans, blood tests, and overall health of each patient. TARE may be considered when:

• Liver tumors cannot be removed with surgery or treated with ablation (heat- or cold-based destruction of a tumor) because of their size, number, or location.
• The cancer is mostly or entirely confined to the liver, with little or no disease elsewhere in the body.
• The patient’s liver still works reasonably well, as judged by blood tests such as bilirubin and albumin and by clinical scoring systems.
• The goal is to shrink tumors before surgery, to control disease while a patient waits for a liver transplant, or to slow progression when a cure is not possible.
• The tumor has grown into a major liver vein (portal vein). TARE is sometimes preferred over chemoembolization in this situation because it depends less on blocking blood flow.

TARE is generally not suitable when:

• Liver function is severely reduced, because the healthy liver may not tolerate the radiation and the risk of liver failure rises.
• A planning scan shows that too much of the radioactive material would travel to the lungs (a “lung shunt”) and cause radiation injury there.
• Blood vessels cannot be arranged so that the beads avoid the stomach, intestines, or pancreas, where they could cause ulcers.
• The cancer has spread widely outside the liver, in which case body-wide treatments such as chemotherapy, targeted drugs, or immunotherapy are usually more appropriate.
• The patient is too unwell to undergo the procedure, has uncontrolled infection, or has a blocked bile duct that has not been treated.

Your doctors will weigh these factors individually. Being told that TARE is not the right option does not mean there are no other treatments.

How the transarterial radioembolization procedure works, step by step

The transarterial radioembolization procedure is carried out in two separate sessions, typically one to three weeks apart. The first session is a planning or “mapping” study, and the second is the actual treatment.

Before: the mapping angiogram

An angiogram is an X-ray examination of blood vessels using a contrast dye. During the mapping session, the interventional radiologist inserts a catheter through an artery in the wrist or groin, guides it into the liver arteries, and takes detailed pictures. This shows exactly which vessels supply the tumor and which supply the stomach or intestine. Small side vessels that could carry beads to the wrong organ may be closed off with tiny coils. A harmless tracer substance is then injected, and a nuclear medicine scan measures how much of it reaches the lungs. The team uses these results to calculate a safe, personalized radiation dose. If the mapping study shows too high a lung shunt or unsafe anatomy, the treatment may be modified or canceled.

During: the treatment session

The treatment session follows a similar path. Most patients receive local anesthesia (numbing medicine at the puncture site) together with light sedation to help them relax; general anesthesia is rarely needed. Once the catheter is positioned in the target vessel, the radioactive microspheres are slowly injected under X-ray guidance. The beads travel with the blood and become trapped in the small vessels of the tumor. Because the radiation from Y-90 only travels a few millimeters in tissue, most of the dose is absorbed by the tumor and its immediate surroundings. The injection itself takes minutes; the whole session, including catheter placement and imaging, often lasts one to three hours.

After: observation and discharge

The catheter is removed and the puncture site is closed with pressure or a small closure device. Patients typically rest for a few hours while the site is checked. Many centers perform a scan shortly afterward to confirm where the beads settled. Many patients go home the same day or after one night in the hospital, depending on how they feel and on local practice. If only one side of the liver is treated first, a second treatment for the other side may be planned several weeks later.

Preparation for transarterial radioembolization

Careful preparation helps the team deliver the treatment safely. You can generally expect the following:

• Imaging and blood tests. A recent CT or MRI scan of the liver and blood tests for liver function, kidney function, blood counts, and clotting are usually required.
• Medication review. Tell your doctors about every medicine and supplement you take. Blood thinners, some diabetes medicines, and certain kidney-affecting drugs may need to be paused or adjusted before the angiogram. Do not stop any medicine on your own.
• Allergies. Report any previous reaction to contrast dye or to local anesthetics.
• Fasting. You will typically be asked not to eat for several hours before each session, although clear fluids and essential medicines may be allowed.
• Protective medicines. Your team may prescribe acid-reducing medicine to protect the stomach lining, and sometimes short courses of steroids or anti-nausea drugs.
• Practical arrangements. Because of the sedation, you will need someone to take you home. Wear comfortable clothing and leave jewelry at home.

You will also be asked to sign a consent form after the risks and benefits have been explained. This is a good time to ask questions about what to expect.

Recovery and aftercare: transarterial radioembolization recovery time

Transarterial radioembolization recovery time is usually shorter than recovery from liver surgery, but the experience varies from person to person. In the first days, many patients notice tiredness, mild fever, loss of appetite, nausea, or a dull ache in the upper right abdomen. Together these symptoms are sometimes called post-embolization syndrome, and they are usually managed with rest, fluids, and simple medicines. Fatigue is the most common complaint and can last two to four weeks; some people feel more tired for longer.

Practical aftercare points include:

• Puncture site. Keep the site clean and dry for a day or two. Avoid heavy lifting and strenuous exercise for several days, or as advised.
• Radiation precautions. The radiation from Y-90 mostly stays inside the liver, and the risk to others is very low. Even so, centers often advise limiting prolonged close contact with pregnant women and small children for a short period, typically about a week, and following simple hygiene steps. Your team will give specific written instructions.
• Medicines. Take any prescribed stomach-protecting, anti-nausea, or pain medicines as directed.
• Eating and drinking. Small, frequent meals and plenty of fluids often help with appetite loss.
• Follow-up. Blood tests are usually repeated within a few weeks, and a follow-up scan is typically scheduled about one to three months after treatment, because the full effect of the radiation takes time to appear on imaging.

Many patients return to light daily activities within a few days and to their normal routine within a few weeks, although the exact transarterial radioembolization recovery time depends on liver health, tumor burden, and other treatments being given at the same time.

Transarterial radioembolization risks and benefits: side effects to expect

Understanding transarterial radioembolization risks and benefits helps you make an informed decision with your care team.

Common, usually temporary side effects

• Fatigue, often the most noticeable effect.
• Abdominal pain or discomfort, usually mild to moderate.
• Nausea, reduced appetite, and occasional vomiting.
• Low-grade fever in the first days.
• Bruising or soreness at the puncture site.
• Temporary changes in liver blood tests.

Less common but more serious complications

• Radiation-induced liver disease (REILD): injury to healthy liver tissue that can cause jaundice (yellowing of the skin and eyes), fluid buildup in the abdomen, and in severe cases liver failure. The risk is higher when liver function is already poor or when a large part of the liver is treated.
• Stomach or duodenal ulcers: if beads reach the digestive tract, they can cause painful ulcers that are slow to heal. Careful mapping is designed to prevent this.
• Radiation pneumonitis: lung inflammation if too much radiation reaches the lungs; the planning scan is intended to exclude patients at risk.
• Biliary complications: inflammation of the gallbladder or bile ducts, or narrowing of bile ducts.
• Infection or abscess in the liver.
• Vascular injury, bleeding, or contrast-dye reaction related to the angiogram itself.

Benefits

The main advantages of TARE are that it treats the liver directly while sparing most of the body from radiation, that it is performed through a small puncture rather than an incision, and that recovery is generally faster than after surgery. It can often be given when other liver-directed treatments are not possible, and it is frequently combined with drug therapies. Whether the benefits outweigh the risks depends on your individual situation.

Results and outlook

The evidence generally shows that transarterial radioembolization can shrink or control liver tumors in a meaningful proportion of patients and is well tolerated by many. In hepatocellular carcinoma, studies have found that TARE achieves disease control in the treated liver comparable to chemoembolization, often with fewer hospital days and less post-procedure discomfort. It has also been used successfully to shrink tumors so that surgery or ablation becomes possible, and to keep patients within transplant criteria while they wait for a donor organ.

For liver metastases from colorectal cancer, TARE is most often used after standard chemotherapy has stopped working or alongside it. Large trials have shown that it can improve control of disease within the liver, although a clear improvement in overall survival has not been consistently demonstrated in the first-line setting. For neuroendocrine tumor metastases, TARE frequently reduces tumor bulk and hormone-related symptoms.

It is important to understand that TARE is usually not a cure by itself. It is one tool that may be used to slow disease, relieve symptoms, or bridge to another treatment. Response is judged on follow-up scans over several months, because treated tumors may take time to shrink and can look unchanged early on even when the treatment is working. Your oncologist will interpret results in the context of your overall treatment plan.

Cost considerations

The cost of transarterial radioembolization varies considerably between countries, hospitals, and individual cases. Rather than quoting figures, it is more useful to understand what drives the price:

• Two-stage process. The mapping angiogram, nuclear medicine scan, and treatment session each involve procedure room time, imaging, and specialist staff.
• The microspheres themselves. The radioactive device is manufactured to order for a specific date and dose and is typically the single largest component of the cost.
• Hospital stay. Same-day discharge is less costly than an overnight or longer admission, which may be needed if side effects are more pronounced.
• Number of treatments. Treating one liver lobe versus both, or repeating TARE later, changes the total.
• Follow-up. Blood tests, repeat CT or MRI scans, and clinic visits over the following months add to the overall expense.
• Insurance and coverage. Whether TARE is covered, and under what conditions, depends on the payer and the diagnosis.

Patients considering treatment abroad should also factor in travel, accommodation between the two sessions, and the need for follow-up care after returning home.

Frequently asked questions

Is transarterial radioembolization painful?

Most patients describe the transarterial radioembolization procedure as uncomfortable rather than painful. Local anesthetic numbs the puncture site, and sedation helps with relaxation. Some people feel warmth or pressure during the contrast injection. Afterward, a dull ache in the upper abdomen is common for a few days and is usually controlled with ordinary pain relievers.

How long does transarterial radioembolization recovery take?

Transarterial radioembolization recovery time is typically a few days for the puncture site and light activities, and around two to four weeks for fatigue and appetite to return to normal. Some patients take longer, particularly if their liver function was reduced before treatment or if they are also receiving chemotherapy.

Who needs transarterial radioembolization instead of surgery?

Surgery is generally preferred when a tumor can be safely removed. TARE is usually considered for patients whose tumors are too large, too numerous, or too close to major vessels for surgery, or whose overall health makes an operation risky. In some cases TARE is used first to shrink tumors so that surgery later becomes possible.

What are the main transarterial radioembolization risks and benefits?

The key benefits are targeted radiation to the liver, a small puncture instead of an incision, and relatively quick recovery. The main risks are fatigue, abdominal discomfort, and, less commonly, damage to healthy liver tissue, ulcers in the digestive tract, or lung inflammation. Careful patient selection and mapping reduce but do not eliminate these risks.

Am I radioactive after the transarterial radioembolization procedure?

The Y-90 microspheres stay inside the liver, and the radiation they emit travels only a few millimeters. The amount that can reach another person is very small. Hospitals commonly suggest simple precautions for about a week, such as avoiding prolonged close contact with pregnant women and young children. Your team will explain exactly what applies to you.

Can transarterial radioembolization be repeated?

In many cases, yes. If one side of the liver was treated first, the other side is often treated a few weeks later. Repeating TARE in a previously treated area is possible in selected patients, but it depends on how well the liver has recovered and how much healthy tissue remains, so it is decided case by case.

How is TARE different from chemoembolization (TACE)?

Both procedures deliver treatment through the liver arteries. TACE injects chemotherapy drugs together with particles that block blood flow, while TARE relies mainly on radiation from microspheres and blocks vessels only minimally. TARE often causes fewer immediate side effects and can be used when a major liver vein is involved, whereas TACE is more widely available and has a longer track record in some settings.

When to see a doctor

You should be assessed by a liver or cancer specialist if you have a known liver tumor and have been told that surgery is not possible, if scans show new or growing lesions in the liver, or if you have cirrhosis or chronic hepatitis B or C and develop unexplained weight loss, abdominal swelling, persistent pain in the upper right abdomen, or yellowing of the skin or eyes. These situations warrant a review of all treatment options, of which transarterial radioembolization may be one.

After the procedure, seek urgent medical attention if you notice any of the following:

• Fever above 38.5°C (101.3°F) that persists or is accompanied by chills.
• Severe or worsening abdominal pain that is not relieved by prescribed medicine.
• Vomiting blood, passing black or tarry stools, or persistent burning stomach pain, which may indicate an ulcer.
• New yellowing of the skin or eyes, dark urine, or rapidly increasing abdominal swelling.
• Shortness of breath, dry cough, or chest pain.
• Bleeding, expanding swelling, coldness, numbness, or color change in the arm or leg used for the catheter.
• Confusion or unusual drowsiness.

Milder symptoms such as fatigue, reduced appetite, or low-grade fever in the first days are expected, but if they last longer than about two weeks or are getting worse rather than better, contact your treating team for advice.